Characterization of fHbp, nhba (gna2132), nadA, porA, Sequence Type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales

Journal of Clinical Microbiology

Volumn 47, Issue 11, 2009, Pages 3577-3585

  Lucidarme, Jay ^a   Comanducci, Maurizio ^b   Findlow, Jamie ^a   Gray, Stephen J ^a   Kaczmarski, Edward B ^a   Guiver, Malcolm ^a   Kugelberg, Elisabeth ^c   Vallely, Pamela J ^d   Oster, Philipp ^b   Pizza, Mariagrazia ^b   Bambini, Stefania ^b   Muzzi, Alessandro ^b   Tang, Christoph M ^c   Borrow, Ray ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIAL ADHESIN B; NEISSERIAL HEPARIN BINDING ANTIGEN; PORIN A; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE INSERTION SEQUENCE; GENOMICS; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT;

BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; CLUSTER ANALYSIS; DNA FINGERPRINTING; DNA TRANSPOSABLE ELEMENTS; ENGLAND; GENOTYPE; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE DATA; NEISSERIA MENINGITIDIS; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; WALES;

OAT MOSAIC VIRUS;

EID: 70449632740     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00936-09     Document Type: Article

References (39)

1. Bambini, S., A. Muzzi, P. Olcen, R. Rappuoli, M. Pizza, and M. Comanducci. 2009. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27:2794-2803.
2. Bjune, G., E. A. Høiby, J. K. Grønnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nøkleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Froholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
3. Borrow, R., and E. Miller. 2006. Long term protection in children with meningococcal C conjugation vaccination: lessons learned. Expert Rev. Vaccines 6:851-857. (Pubitemid 46021061)
4. Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, J. Mays, et al. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13:821-829.
5. Comanducci, M., S. Bambini, D. A. Caugant, M. Mora, B. Brunelli, B. Capecchi, L. Ciucchi, R. Rappuoli, and M. Pizza. 2004. NadA diversity and carriage in Neisseria meningitidis. Infect. Immun. 72:4217-4223.
6. Comanducci, M., S. Bambini, B. Brunelli, J. Adu-Bobie, B. Aricò, B. Capecchi, M. M. Giuliani, V. Masignani, L. Santini, S. Savino, D. M. Granoff, D. A. Caugant, M. Pizza, R. Rappuoli, and M. Mora. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195:1445-1454.
7. Elias, J., and U. Vogel. 2007. IS1301 fingerprint analysis of Neisseria meningitidis strains belonging to the ET-15 clone. J. Clin. Microbiol. 45:159-167.
8. Feil, E. J., B. C. Li, D. M. Aanensen, W. P. Hanage, and B. G. Spratt. 2004. eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J. Bacteriol. 186:1518-1530.
9. Fletcher, L. D., L. Bernfield, V. Barniak, J. E. Farley, A. Howell, M. Knauf, P. Ooi, R. P. Smith, P. Weise, M. Wetherell, X. Xie, R. Zagursky, Y. Zhang, and G. W. Zlotnick. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088-2100.
10. Giuliani, M. M., J. Adu-Bobie, M. Comanducci, B. Aricò, S. Savino, L. Santini, B. Brunelli, S. Bambini, A. Biolchi, B. Capecchi, E. Cartocci, L. Ciucchi, F. Di Marcello, F. Ferlicca, B. Galli, E. Luzzi, V. Masignani, D. Serruto, D. Veggi, M. Contorni, M. Morandi, A. Bartalesi, V. Cinotti, D. Mannucci, F. Titta, E. Ovidi, J. A. Welsch, D. Granoff, R. Rappuoli, and M. Pizza. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. USA 103:10834-10839.
11. Gray, S. J., C. L. Trotter, M. E. Ramsay, M. Guiver, A. J. Fox, R. Borrow, R. H. Mallard, and E. B. Kaczmarski. 2006. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol. 55:887-896.
12. Hall, T. A. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. 41:95-98.
13. Hammerschmidt, S., R. Hilse, J. P. van Putten, R. Gerardy-Schahn, A. Unkmeir, and M. Frosch. 1996. Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBO J. 15:192-198.
14. Jacobsson, S., S. Thulin, P. Mölling, M. Unemo, M. Comanducci, R. Rappuoli, and P. Olcén. 2006. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 24:2161-2168. (Pubitemid 43255159)
15. Jiang, H. Q., S. L. Harris, C. Tan, A. Scott, K. Alexander, K. Mason, I. DaSilva, M. Mack, X. J. Zhao, S. Guttmann, D. Liu, P. Wong, L. McNeil, M. Pride, A. Arora, D. Zhu, S. K. Hoiseth, T. L. Mininni, M. Hagen, T. Jones, K. U. Jansen, an G. W. Zlotnick. 2008. Prediction of broad vaccine coverage for a bivalent rLP2086 based vaccine which elicits serum bactericidal activity against a diverse collection of serogroup B meningococci, abstr. O41. Abstr. 16th Int. Pathogenic Neisseria Conf.
16. Kelly, C., R. Arnold, Y. Galloway, and J. O'Hallahan. 2007. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol. 166:817-823.
17. Koeberling, O., S. Giuntini, A. Seubert, and D. M. Granoff. 2009. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin. Vaccine Immunol. 16:156-162.
18. Madico, G., J. A. Welsch, L. A. Lewis, A. McNaughton, D. H. Perlman, C. E. Costello, J. Ngampasutadol, U. Vogel, D. M. Granoff, and S. Ram. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510. (Pubitemid 43939163)
19. Reference deleted.
20. Masignani, V., M. Comanducci, M. M. Giuliani, S. Bambini, J. Adu-Bobie, B. Arico, B. Brunelli, A. Pieri, L. Santini, S. Savino, D. Serruto, D. Litt, S. Kroll, J. A. Welsch, D. M. Granoff, R. Rappuoli, and M. Pizza. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799.
21. McNeil, L. K., E. Murphy, X. J. Zhao, S. Guttmann, S. L. Harris, A. A. Scott, C. Tan, M. Mack, I. DaSilva, K. Alexander, K. Mason, H. Q. Jiang, D. Zhu, T. L. Mininni, G. W. Zlotnick, S. K. Hoiseth, T. R. Jones, M. W. Pride, K. U. Jansen, and A. S. Anderson. 2009. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 27:3417-3421.
22. Murphy, E., L. Andrew, K. L. Lee, D. A. Dilts, L. Nunez, P. S. Fink, K. Ambrose, R. Borrow, J. Findlow, M. K. Taha, A. E. Deghmane, P. Kriz, M. Musilek, J. Kalmusova, D. A. Caugant, T. Alvestad, L. W. Mayer, C. T. Sacchi, X. Wang, D. Martin, A. von Gottberg, M. du Plessis, K. P. Klugman, A. S. Anderson, K. U. Jansen, G. W. Zlotnick, and S. K. Hoiseth. 2009. Sequence diversity of the factor h binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200:379-389.
23. Newcombe, J., K. Cartwright, S. Dyer, and J. McFadden. 1998. Naturally occurring insertional inactivation of the porA gene of Neisseria meningitidis by integration of IS1301. Mol. Microbiol. 30:453-454.
24. Pillai, S., A. Howell, K. Alexander, B. E. Bentley, H. Q. Jiang, K. Ambrose, D. Zhu, and G. Zlotnick. 2005. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23:2206-2209.
25. Pizza, M., V. Scarlato, V. Masignani, M. M. Giuliani, B. Aricò, M. Comanducci, G. T. Jennings, L. Baldi, E. Bartolini, B. Capecchi, C. L. Galeotti, E. Luzzi, R. Manetti, E. Marchetti, M. Mora, S. Nuti, G. Ratti, L. Santini, S. Savino, M. Scarselli, E. Storni, P. Zuo, M. Broeker, E. Hundt, B. Knapp, E. Blair, T. Mason, H. Tettelin, D. W. Hood, A. C. Jeffries, N. J. Saunders, D. M. Granoff, J. C. Venter, E. R. Moxon, G. Grandi, and R. Rappuoli. 2000. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816-1820.
26. Rosenqvist, E., E. A. Høiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Rønnild, G. Bjune, and H. Nøkleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
27. Schneider, M. C., R. M. Exley, H. Chan, I. Feavers, Y. H. Kang, R. B. Sim, and C. M. Tang. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176:7566-7575.
28. Segal, S., and A. J. Pollard. 2005. Vaccines against bacterial meningitis. Br. Med. Bull. 72:65-81.
29. Sexton, K., D. Lennon, P. Oster, S. Crengle, D. Martin, K. Mulholland, T. Percival, S. Reid, J. Stewart, and J. O'Hallahan. 2004. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. N. Z. Med. J. 117:U1015.
30. Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-207.
31. Tamura, K., J. Dudley, M. Nei, and S. Kumar. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596-1599.
32. Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. Høiby, J. Holst, H. Nøkleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527.
33. Tettelin, H., N. J. Saunders, J. Heidelberg, A. C. Jeffries, K. E. Nelson, J. A. Eisen, K. A. Ketchum, D. W. Hood, J. F. Peden, R. J. Dodson, W. C. Nelson, M. L. Gwinn, R. DeBoy, J. D. Peterson, E. K. Hickey, D. H. Haft, S. L. Salzberg, O. White, R. D. Fleischmann, B. A. Dougherty, T. Mason, A. Ciecko, D. S. Parksey, E. Blair, H. Cittone, E. B. Clark, M. D. Cotton, T. R. Utterback, H. Khouri, H. Qin, J. Vamathevan, J. Gill, V. Scarlato, V. Masignani, M. Pizza, G. Grandi, L. Sun, H. O. Smith, C. M. Fraser, E. R. Moxon, R. Rappuoli, and J. C. Venter. 2000. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287:1809-1815. (Pubitemid 30143964)
34. Uria, M. J., Q. Zhang, Y. Li, A. Chan, R. M. Exley, B. Gollan, H. Chan, I. Feavers, A. Yarwood, R. Abad, R. Borrow, R. A. Fleck, B. Mulloy, J. A. Vazquez, and C. M. Tang. 2008. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J. Exp. Med. 205:1423-1434.
35. Reference deleted.
36. Welsch, J. A., G. R. Moe, R. Rossi, J. Adu-Bobie, R. Rappuoli, and D. M. Granoff. 2003. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis. 188:1730-1740.
37. Weynants, V., P. Denoël, N. Devos, D. Janssens, C. Feron, K. Goraj, P. Momin, D. Monnom, C. Tans, A. Vandercammen, F. Wauters, and J. T. Poolman. 2009. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect. Immun. 77:2084-2093.
38. Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:514-521.
39. Zollinger, W. D., M. Donets, B. L. Brandt, B. Ionin, E. E. Moran, D. Schmiel, V. Pinto, M. Fisseha, J. Labrie, R. Marques, and P. Keiser. 2008. Multivalent group B meningococcal vaccine based on native outer membrane vesicles (NOMV) has potential for providing safe, broadly protective immunity, abstr. O35. Abstr. 16th Int. Pathogenic Neisseria Conf.